Ariad leukemia drug Iclusig makes swift US return, but under restrictions
This article was originally published in Scrip
Executive Summary
To say the least, "it's been a challenging two months" for Ariad Pharmaceuticals after its oral leukemia drug Iclusig (ponatinib) had a sudden departure in late October from the US market, Chairman, President and CEO Dr Harvey Berger acknowledged.